Edgestream Partners L.P. Has $2.87 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Edgestream Partners L.P. increased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 82.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 99,401 shares of the company’s stock after buying an additional 44,829 shares during the period. Edgestream Partners L.P.’s holdings in Apellis Pharmaceuticals were worth $2,867,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. Braidwell LP grew its stake in shares of Apellis Pharmaceuticals by 410.8% in the 3rd quarter. Braidwell LP now owns 3,125,183 shares of the company’s stock valued at $90,130,000 after buying an additional 2,513,383 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of Apellis Pharmaceuticals by 191.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock valued at $61,845,000 after buying an additional 1,409,707 shares during the period. Fiera Capital Corp grew its stake in shares of Apellis Pharmaceuticals by 47.7% in the 2nd quarter. Fiera Capital Corp now owns 1,401,190 shares of the company’s stock valued at $53,750,000 after buying an additional 452,753 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Apellis Pharmaceuticals by 1.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 956,362 shares of the company’s stock valued at $27,581,000 after buying an additional 9,328 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in shares of Apellis Pharmaceuticals by 6.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 345,195 shares of the company’s stock valued at $13,242,000 after buying an additional 22,273 shares during the period. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Trading Down 0.6 %

Shares of APLS stock opened at $33.93 on Monday. The company’s fifty day simple moving average is $28.72 and its two-hundred day simple moving average is $35.25. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals, Inc. has a 1 year low of $24.34 and a 1 year high of $73.80. The stock has a market capitalization of $4.22 billion, a price-to-earnings ratio of -16.71 and a beta of 0.87.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The firm had revenue of $196.83 million for the quarter, compared to analysts’ expectations of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm’s revenue for the quarter was up 78.3% on a year-over-year basis. During the same quarter last year, the firm earned ($1.17) earnings per share. As a group, analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on APLS. Piper Sandler cut their price target on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating for the company in a research note on Wednesday, November 6th. Morgan Stanley began coverage on Apellis Pharmaceuticals in a research note on Thursday, November 21st. They set an “equal weight” rating and a $31.00 price target for the company. JPMorgan Chase & Co. cut their price target on Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating for the company in a research note on Friday, September 13th. Royal Bank of Canada reiterated a “sector perform” rating and set a $25.00 price target on shares of Apellis Pharmaceuticals in a research note on Monday, November 4th. Finally, William Blair began coverage on Apellis Pharmaceuticals in a research note on Wednesday, October 16th. They set an “outperform” rating for the company. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Apellis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $49.94.

Insider Buying and Selling

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $36.23, for a total value of $1,340,510.00. Following the completion of the sale, the director now directly owns 100,000 shares of the company’s stock, valued at $3,623,000. The trade was a 27.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 6.80% of the stock is owned by company insiders.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).